Helen S. Kim is a Managing Director of Vida Ventures, a life sciences focused venture capital firm.
Ms. Kim has over 28 years of experience in leadership roles in biotechnology. Most recently, Ms. Kim was a Partner at The Column Group. Prior, Ms. Kim served as Executive Vice President of Business Development at Kite Pharma, Inc. where she led all business and corporate development initiatives successfully selling Kite Pharma to Gilead in 2017.
Previously, Ms. Kim served as Strategic Advisor of NGM Biopharmaceuticals, Inc. from January 2012 through November, 2014. Ms. Kim served as the Chief Business Officer at NGM Biopharmaceuticals, Inc. from August 2009 to January 2012. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb in 2008. Ms. Kim’s additional industry experience includes executive positions at Affymax, Onyx Pharmaceuticals and Chiron Corporation. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago.
Ms. Kim currently serves on the Board of Directors for Assembly Biosciences, Applied Molecular Transport, PACT Pharma, ReCode, A2 Bio and Iconovir. She is a Board Observer for Locana Bio and Innoskel.